Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antithrombotic agents

A technique for thrombolytic agent and thromboembolism, applied in the field of monoclonal antibody and its use as a thrombosis inhibitor, can solve the problems of deterioration of ischemic injury and the like

Inactive Publication Date: 2004-06-02
SMITHKLINE BECKMAN CORP
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, thrombolytic therapy is associated with a severe bleeding tendency, and in the thrombolytic therapy of thromboembolic stroke, the main concern is that the treatment will worsen the ischemic injury by inducing hemorrhage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antithrombotic agents
  • Antithrombotic agents
  • Antithrombotic agents

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0130] Preparation and Screening of Anti-Factor IX Monoclonal Antibodies

[0131] Female Balb / C mice were injected with human factor IX purified as described by Jenny, R. et al., Prep Biochem, 16, 227-245 (1986). Typically, each mouse receives an initial injection of 1000 g of protein dissolved in 0.15 mL of phosphate-buffered saline (PBS) mixed with 0.15 mL of complete Freund's adjuvant. During 2-3 months, 500 g of protein dissolved in 0.15 mL of PBS and 0.15 mL of incomplete Freund's adjuvant was injected every two weeks for booster immunization. After the last booster injection, mice received 3 days before spleen / myeloma cell fusion 500 g of Factor IX in PBS. Splenocytes were isolated from immunized mice and followed by Oi, V.T. et al. in "Selected Methods in Cellular Immunology," Mishell, B.B. and Shigii, S.M., eds., Freeman Press, San Francisco A method described in a book, using polyethylene glycol to fuse spleen cells with NS-1 myeloma cells (Kohler, G. et al., Eur J...

Embodiment 2

[0135] Self-limiting role of anti-coagulation factor antibodies in blood coagulation

[0136] The effect of increasing anti-coagulation factor antibody concentrations on human plasma activation was determined in a fibrometer (Becton-Dickinson Microbiology Systems, Cockeysville, Maryland) using the Baxter reference program LIB0293-J, version 3 / 93 (Baxter Scientific, Edison, New Jersey). Effect of partial thromboplastin time (aPTT).

[0137] Before starting this test, filled with 2 ~ 3mL 0.02M CaCl 2 Put the 5mL test tube into the heating chamber of the fibrometer. Human plasma samples were obtained either from freshly collected blood stored in an ice bath or reconstituted by Hemostasis Reference Plasma (American Diagnostics, Greenwich, Connecticut) according to the manufacturer's instructions.

[0138] Unfractionated heparin from porcine intestinal mucosa (Sigma Chemical, St.Louis, Missouri), low molecular weight heparin from intestinal mucosa (Lovenox®, enoxaparin sodium, ...

Embodiment 3

[0160] Efficacy of murine factor IX mAbs in rat thrombus model

[0161] To evaluate the efficacy of anti-factor IX antibodies in preventing arterial thrombosis, the rat carotid artery thrombosis model reported by Schumacher et al., J Cardio Pharm, 22, 526-533 (1993) was used. The model is constructed as follows: FeCl 3 Oxygen radicals generated by the solution are applied on the surface of the carotid artery causing segmental damage to the carotid endothelium.

[0162] Briefly, rats were anesthetized with sodium pentobarbital, the jugular vein cannulated for intravenous injection, and the left femoral artery was cannulated for blood pressure and heart rate monitoring. The carotid artery was aseptically isolated through a surgical incision in the neck and equipped with a magnetic flow probe to measure blood flow. After a period of stabilization, baseline parameters were established for the following variables: carotid blood flow, arterial pressure, heart rate, activated par...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Monoclonal antibodies directed against coagulation factor IX and their use in inhibiting thrombosis are disclosed.

Description

field of invention [0001] The present invention relates to monoclonal antibodies (mAbs) that bind to human coagulation factors or cofactors and their use as inhibitors of thrombosis. Background of the invention [0002] Under normal conditions, damage to the vascular endothelial cells of the vascular intimal membrane, regardless of the size of the damage, will trigger a hemostatic response through a series of events commonly referred to as the coagulation "cascade". This cascade reaction culminates in the conversion of soluble fibrinogen to insoluble fibrin, which together with platelets forms a local blood clot or thrombus that prevents extravasation of blood components. Wound healing then occurs as the clot dissolves and vascular integrity is repaired and blood flow restored. [0003] The events that occur between injury and clot formation are finely regulated and linked by a series of responses. Briefly, large amounts of plasma coagulation proteins and cofactors circula...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/46A61K39/395A61P7/02C07K16/36C07K16/40
CPCC07K16/40A61K2039/505C07K16/36C07K2317/24A61P3/00A61P7/02A61P9/00A61P9/10A61K39/395
Inventor 弗兰克·C·巴龙迈克尔·N·布莱克本乔拉·Z·福伊尔斯坦约翰·R·图米
Owner SMITHKLINE BECKMAN CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com